DEVELOPMENT PIPELINE

We are leveraging our proprietary SNIPRx platform to discover, validate and build a robust clinical and pre-clinical pipeline of SL-based oncology therapeutics.

Development Pipeline

Program
Tumor Lesion
  • Discovery
  • IND-Enabling
  • Ph 1/2
  • Pivotal
Rights

Lunresertib
PKMYT1 Inhibitor

CCNE1,
FBXW7 + others
  • Ph 1/2
Ph2 CCTG ISTs
  • Ph 1/2
Ph1 MYTHIC: Mono + Camonsertib Combo
  • Ph 1/2
Ph1 MAGNETIC: Gemcitabine Combo
  • Ph 1/2
Ph1 MINOTAUR: FOLFIRI Combo
  • Ph 1/2
Ph 1 Carboplatin/paclitaxel Combo IST
  • Ph 1/2
Ph1/1b Debio 0123 Combination
repare logo small

Camonsertib
ATR Inhibitor

ATM + 16 lesions
  • Ph 1/2
Ph2 TAPISTRY
  • Ph 1/2
Ph1b/2 Morpheus-Lung
  • Ph 1/2
Ph1/2 TRESR: Mono + PARP (talazoparib) Combo
  • Ph 1/2
Ph1/2 ATTACC: PARP (olaparib/niraparib) Combo
  • Ph 1/2
Ph1/2 TRESR: Gemcitabine Combo
repare logo small

RP-1664
PLK4 Inhibitor

TRIM37-high
  • Ph 1/2
Ph1 LIONS Monotherapy
repare logo small

RP-3467
Polθ ATPase Inhibitor

BRCA1/2 + others
  • IND.
repare logo small

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small
Targets
PKMYT1 Inhibitor
Tumor Lesion
CCNE1,
FBXW7 + others
Clinical Trial
Ph2 CCTG ISTs
Progress
Phase 1/2
Clinical Trial
Ph1 MYTHIC: Mono + Camonsertib Combo
Progress
Phase 1/2
Clinical Trial
Ph1 MAGNETIC: Gemcitabine Combo
Progress
Phase 1/2
Clinical Trial
Ph1 MINOTAUR: FOLFIRI Combo
Progress
Phase 1/2
Clinical Trial
Ph 1 Carboplatin/paclitaxel Combo IST
Progress
Phase 1/2
Clinical Trial
Ph1/1b Debio 0123 Combination
Progress
Phase 1/2
Rights
Repare
Targets
ATR Inhibitor
Tumor Lesion
ATM + 16 lesions
Clinical Trial
Ph2 TAPISTRY
Progress
Phase 1/2
Clinical Trial
Ph1b/2 Morpheus-Lung
Progress
Phase 1/2
Clinical Trial
Ph1/2 TRESR: Mono + PARP (talazoparib) Combo
Progress
Phase 1/2
Clinical Trial
Ph1/2 ATTACC: PARP (olaparib/niraparib) Combo
Progress
Phase 1/2
Clinical Trial
Ph1/2 TRESR: Gemcitabine Combo
Progress
Phase 1/2
Rights
Repare
Targets
PLK4 Inhibitor
Tumor Lesion
TRIM37-high
Clinical Trial
Ph1 LIONS Monotherapy
Progress
Phase 1/2
Rights
Repare
Targets
Polθ ATPase Inhibitor
Tumor Lesion
BRCA1/2 + others
Progress
IND. Enabling
Rights
Repare
Targets
Multiple Targets
Tumor Lesion
Undisclosed
Progress
Discovery
Rights
Repare
Targets
Multiple Targets
Tumor Lesion
Undisclosed
Progress
Discovery
Rights
Bristol Myers Squibb

Learn about our collection of ongoing clinical trials.